Prostate Tissue BioBank
Status
RECRUITING
Phase
Age
≥ 18 Years
Enrollments
200Conditions
Prostate Cancer, Genetic PredispositionSummary
Prostate cancer is also the most common cancer in men with inherited pathogenic variants in BRCA1 and BRCA2. Beyond BRCA1/2, other genes are known to increase the risk of prostate cancer, including ATM, TP53 and HOXB13. We have shown that 5% of men diagnosed with prostate cancer localized to their prostate gland and up to 10-15% of patients with metastatic prostate cancer gland are carriers of an inherited gene mutation.The Prostate Tissue BioBank is a prospective study which aims to create a biorepository of prostate tissue samples from prostate biopsies and prostatectomies and matched germline DNA from pathogenic mutation carriers in addition to age-matched control samples. Our primary goal is to investigate prostate cancer development and treatment response in carriers of germline DNA repair mutations, as compared to non-carrier controls.
Locations
1 location Found with status Recruiting
Status
- RECRUITING
Contact Person
- Kara N Maxwell, MD, PhD
- 215-898-9698
Principal Investigator
- Kara N Maxwell, MD, PhD
Eligibility Criteria
Inclusion Criteria:
Carriers (Group 1):
1. Confirmed pathogenic or likely pathogenic variant in a known prostate cancer risk gene.
2. Patients undergoing prostate biopsies as a part of their prostate cancer screening OR biopsy or prostatectomy due to a diagnosis of prostate cancer
Controls (Group 2):
1. Patients undergoing prostate biopsies as a part of their prostate cancer screening OR biopsy or prostatectomy due to a diagnosis of prostate cancer
Exclusion Criteria:
* N/A
Study Plan
Carriers
Eligible subjects will have confirmed pathogenic or likely pathogenic variants in a prostate cancer risk gene, and will also be undergoing prostate needle biopsy, prostatectomy or metastatic biopsy. Study participation will request access to medical information, blood and tissue samples.
Controls
Eligible subjects will be undergoing prostate needle biopsy, prostatectomy or metastatic biopsy. Study participation will request access to medical information, blood and tissue samples.
Outcome Measures
Primary Outcome Measures
Clinical and pathological data for patients with prostate tissue samples
Timeline
Last Updated
October 26, 2024Start Date
October 26, 2024Today
May 12, 2025Completion Date ( Estimated )
January 1, 2034
Sponsors of this trial
Lead Sponsor
Abramson Cancer Center at Penn Medicine
RECRUITING 
≥ 18 Years